Ardabil University of Medical Sciences

Low-Dose Aspirin Evaluated for Gastric Cancer Prevention in High-Risk Iranian Population

- A phase III randomized controlled trial is underway in Iran to assess the effectiveness of long-term, low-dose aspirin in preventing gastric cancer. - The study aims to enroll 21,000 participants aged 35-70 in Ardabil, a region with a high incidence of gastric cancer and _H. pylori_ prevalence. - Participants will receive either 81 mg of enteric-coated aspirin or a placebo daily for 10 years, with outcomes measured 5 years after treatment. - The primary outcome is the difference in the cumulative incidence rate of gastric cancer between the aspirin and placebo groups.